# Aclarion (ACON) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/ACON
## Company Profile
- Ticker: ACON
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
## Stock Data
- Close: 2.14 USD
- Market cap: 8617875 USD
- Last updated: 2026-10-13
## Business Overview
### Chronic Low-Back-Pain Diagnostics
Aclarion develops technology to help physicians identify which lumbar discs may be generating chronic low-back pain. Its approach combines magnetic resonance spectroscopy, biochemical biomarkers, signal processing and augmented-intelligence algorithms.
### Nociscan Platform
Nociscan is a software-as-a-service platform that analyzes disc chemistry noninvasively and classifies discs as more likely painful or nonpainful. Physicians use the information alongside imaging and other diagnostic tools when selecting treatment targets.
### Evidence and Reimbursement Strategy
Aclarion is supporting Nociscan with multiple clinical and real-world evidence studies. The evidence program is intended to demonstrate treatment-selection value and establish commercial-insurance coverage pathways.
## Why The Stock Is Moving

As of Oct 13, 2026, ACON closed down 4.68% at $2.14. No new same-company headline was identified in the current news window.

## Future Catalysts

- Preliminary internal CLARITY trial readout expected in the second half of 2026.
- Public disclosure of early interim CLARITY results anticipated in the fourth quarter of 2026.

## Recent News
- 2026-10-08 11:00 EST — [Aclarion Broadens CLARITY Trial Enrollment Criteria to Accelerate Enrollment](https://biopharmsignal.com/news/ACON/aclarion-broadens-clarity-trial-enrollment-criteria-to-accelerate-enrollment-63c17581) — Source: Aclarion
- 2026-09-29 11:00 EST — [Aclarion Welcomes NYU Langone Health to CLARITY Trial Network, Now Enrolling at Eleven Sites](https://biopharmsignal.com/news/ACON/aclarion-welcomes-nyu-langone-health-to-clarity-trial-network-now-enrolling-at-e-a7649e22) — Source: Aclarion
- 2026-08-20 11:00 EST — [Aclarion Announces Addition of University of Arizona College of Medicine – Phoenix as CLARITY Trial Site](https://biopharmsignal.com/news/ACON/aclarion-announces-addition-of-university-of-arizona-college-of-medicine-phoenix-a28e2040) — Source: Aclarion
- 2026-08-12 11:00 EST — [Aclarion Receives Notice of Allowance for Patent Advancing Accuracy and Adoption of Nociscan's MR Spectroscopy (MRS) Scan Process](https://biopharmsignal.com/news/ACON/aclarion-receives-notice-of-allowance-for-patent-advancing-accuracy-and-adoption-301d05ed) — Source: Aclarion
- 2026-08-04 11:00 EST — [Aclarion Announces Nociscan® Now Available at Goodman Campbell Brain & Spine at Ascension St. Vincent, First Site in Indiana to Offer the Technology](https://biopharmsignal.com/news/ACON/aclarion-announces-nociscan-now-available-at-goodman-campbell-brain-spine-at-asc-6d220f84) — Source: Aclarion